The U.S. Department of State announced the expansion of its partnership with Gilead Sciences and The Global Fund to increase access to lenacapavir (LEN), a breakthrough HIV prevention medication.
LEN is a twice-yearly injectable medication, which has shown 99.9 percent effectiveness at preventing HIV in large-scale clinical trials. Expanding upon its initial market shaping investment in access to LEN, the State Department said it is now growing its commitment to reach an additional 1 million people in high-burden countries with the two-dose annual regimen. Following the announcement, the United States and The Global Fund are committed to reach three million people in high-burden countries with LEN by 2028.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.